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lung cancer (NSCLC). Methods: A Markov Model was developed to evaluate the 
disease progression of a cohort of patients with ALK +ve advanced NSCLC in a three 
year period, that will be treated with Crizotinib. The model compares scenarios With 
and Without Crizotinib. The difference in total costs is the net impact of Crizotinib 
on the health care budget. Local epidemiologic data was used. Costs were estimated 
from Panama Public Health System ($US, 2012) and included costs of treatment, 
administration and monitoring, palliative care, and severe adverse events. The base 
case scenario assumes 100% testing rate for ALK in incident patients and 100% 
market share for crizotinib in ALK+Ve advanced NSCLC patients. Sensitivity analy-
ses were performed for 80-100% market share [3] Results: In a three year period, 
23 patients received Crizotinib (from a cohort of 609 advanced NSCLC patients). 
Cost related to drug acquisition and management of adverse in a world “With” and 
“Without” Crizotinib during three years are $13.426.918 and $12.670.537 respec-
tively which represents $756.381 of budget impact associated with the insertion of 
Crizotinib in the market, however it shows savings in terms of drug administration, 
monitoring costs and progression cost, with an estimated of $471.952 (Difference 
between the two scenarios of $3.931.399 and $4.403.351). Net budget Impact for the 
three year period is $284.428, which represents for the first year ($48.997, $0.0018 
per patient-per month [PMPM]) approximately 0.00289% of Panama’s Total Public 
Health Expenditure (2011). [4] If the Crizotinib market share is assumed to be 80%, 
the net impact was $92.996. ConClusions: Crizotinib for the treatment of ALK+ 
NSCLC patients has a minimal incremental budget impact on the overall expendi-
ture within the Panama Health System.
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objeCtives: Newly diagnosed glioblastoma multiforme (GBM) is associated with 
poor prognosis and limited treatment options. The placebo controlled AVAglio 
study demonstrated that the addition of bevacizumab to radiotherapy (RT) plus 
temozolomide (TMZ) improves progression-free survival (PFS) by 4.4 months, and 
maintains health-related quality of life in patients with newly diagnosed GBM. A 
budget impact model (BIM) has been developed to calculate the costs associated 
with the introduction of bevacizumab for the treatment of newly diagnosed GBM in 
the UK. Methods: The BIM is based on UK epidemiological and resource data and 
compares a base case in which all eligible patients are treated with radiotherapy + 
TMZ only with a scenario in which bevacizumab is introduced with increased uptake 
over a three year period. The model combines drug, adverse events, and administra-
tive costs to estimate the total cost of treating the eligible patient population in the 
UK using published sources converted into £ (2013). Results: The BIM estimates 
that, in year 1, with an expected 10% uptake of bevacizumab, the total cost would be 
£5,619,457, £11,463,690 in year 2, with an expected uptake of 20%, and £16,688,655 
in year 3, with an expected uptake of 30%. When these costs are considered in the 
context of the total oncology costs for the UK in 2013, the budget impact of the intro-
duction of bevacizumab in years 1, 2 and 3 is 0.08 %, 0.17% and 0.25%, respectively. 
When the costs related to bevacizumab alone are considered in the context of the 
total oncology drug budget for the UK in 2013, the costs for bevacizumab for years 
1, 2 and 3 are 0.42%, 0.95 % and 1.43% of the budget, respectively. ConClusions: 
The introduction of bevacizumab for the treatment of newly diagnosed GBM in the 
UK is associated with a low budget impact.
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objeCtives: To estimate the budget impact of bevacizumab plus chemotherapy 
for first and second line metastatic colorectal cancer (mCRC) treatment compared 
with chemotherapy with anti-EGFR for first line and bevacizumab plus chemo-
therapy for second line according to the Russian health care system. Methods: 
The budget impact analysis was conducted. Direct expenses associated with mCRC 
and resulting follow-up costs were calculated using general tariff agreement of 
Russian statutory health insurance and official national statistics (accepted 
exchange rate was 1 $ = 30 RUB). Results: Bevacizumab plus chemotherapy 
for first and second line in the mCRC therapy provided cost saving benefits com-
pared with chemotherapy with anti-EGFR for first line and bevacizumab plus 
chemotherapy for second line. Total health care costs of mCRC therapy were 
approximately 1 145 826 RUB (38 194 $) in bevacizumab+FOLFOX 1 line therapy, 
544 905 RUB (18 164 $) in bevacizumab+FOLFIRI 2 line therapy and 2 957 187 RUB 
(98 573 $) in panitumumab+FOLFOX4 1 line therapy, 872 226 RUB (29 074 $) in 
bevacizumab+FOLFOX4 2 line therapy. Treatment of mCRC using bevacizumab 
treatment combinations compared to chemotherapy with anti-EGFR leads to cost 
savings of 2 138 681 RUB (71 289 $). ConClusions: The results of budget impact 
analysis illustrate that bevacizumab treatment combinations in the mCRC treat-
ment in comparison with chemotherapy with anti-EGFR has potential to reduce 
Russian health care system total costs for mCRC treatment.
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objeCtives: To estimate the burden of disease and costs associated with smok-
ing in Colombia. Methods: Epidemiological data was retrieved from the National 
Administrative Department of Statistics (DANE), Integrated Information System 
on Social Protection (SISPRO) and National Survey of Substance abuse 2008 data-
bases. Costs are expressed in 2012 prices and were obtained from local studies and 
regional approximations. A micro-simulation first order Monte Carlo model was 
constructed, incorporating natural history, costs and quality of life of the most 
important diseases related with smoking: stroke, Coronary Heart Disease (CHD), 
Chronic Obstructive Pulmonary Disease (COPD), and lung cancer. The model was 
programmed in Excel (Microsoft Excel ® Office Professional Edition 2003) with Visual 
Basic ® Macros (Microsoft Visual Basic® 6.3). A software package was installed to 
improve the random number generator function in Excel®. Results: 15.9% of the 
total annual deaths in Colombia are attributable to smoking (6,776 heart disease, 
6,619 COPD, 3,544 lung cancer and 1,831 stroke). Smoking is responsible for 112,891 
hospital admission and it is estimated that 10,606 people are diagnosed annually 
with cancer caused by smoking. The direct health care costs associated with smok-
ing is USD$ 1.692 million dollars (USD$863,103,308 heart diseases, USD$442,619,734 
COPD, USD$ 170,000,285 lung cancer and USD$216,852,028 stroke). ConClusions: 
Smoking is directly responsible for the loss of 674.262 lives each year in Colombia 
and generates an annual direct health care cost of more than 4 billion Colombian 
pesos, equivalent to 0.6% of Colombian GDP and 10.5% of health care spending. 
These results could be useful for decision makers to reinforce public policies regard-
ing smoking cessation in Colombia.
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objeCtives: To estimate the budget impact of bevacizumab combinations in the 
metastatic colorectal cancer (mCRC) treatment and chemotherapy with anti-EGFR 
for first and second line according to the Russian health care system. Methods: 
The budget impact analysis was conducted. Direct expenses associated with 
mCRC and resulting follow-up costs were calculated using general tariff agree-
ment of Russian statutory health insurance and official national statistics (accepted 
exchange rate was 1 $ = 30 RUB). Results: Bevacizumab treatment combinations 
in the mCRC therapy provided cost saving benefits compared with chemotherapy 
with anti-EGFR for first and second line therapy. Total health care costs of mCRC 
therapy were approximately 1 187 115 RUB (39 571 $) in bevacizumab+FOLFIRI 1 
line therapy, 662 242 RUB (22 075 $) in bevacizumab+CAPOX 2 line therapy and 2 
518 311 RUB (83 944 $) in cetuximab+FOLFIRI 1 line therapy, 872 226 RUB (29 074 $) 
in bevacizumab+FOLFOX4 2 line therapy. Treatment of mCRC using bevacizumab 
treatment combinations compared to chemotherapy with anti-EGFR leads to cost 
savings of 1 541 181 RUB (51 373 $). ConClusions: The results of budget impact 
analysis illustrate that bevacizumab treatment combinations in the mCRC treat-
ment in comparison with chemotherapy with anti-EGFR has potential to reduce 
Russian health care system total costs for mCRC treatment.
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objeCtives: To analyze the budget impact of the use of nilotinib in first and second 
line chronic myeloid leukemia (CML), compared with imatinib and dasatinib, from 
the perspective of a third party payer in Colombia. Methods: A Markov model 
was developed with a 5-year time horizon simulating first and second line treat-
ment of CML patients, with treatment options including nilotinib, imatinib and 
dasatinib. 2013 incidence and prevalence figures were estimated from international 
data. Base case market share for each compound was obtained from public national 
medicines registry (Sismed) for the years 2012 – 2013. Resource utilization and costs 
of medicines, health care services and adverse events were estimated according to 
clinical trials data and local health care provider databases. The analysis estimated 
up to 80% market share for nilotinib in both lines. A univariate sensitivity analy-
sis was developed to identify the effect of individual parameter variation on final 
results. Results: Nilotinib inclusion as a first and second line treatment option 
for CML patients resulted in a cumulative impact of COP $14.961 million over 5 
years, corresponding to a 0.056% per capita premium (UPC) in the Colombian care 
health system. Year to year, the impact was calculated from COP $1,168 million to 
COP $6,588 million on the fifth year. The sensitivity analysis showed the costs of 
technologies, health care services and disease progression as the most relevant 
variables. ConClusions: The budget impact analysis showed that increasing the 
use of nilotinib both in first and second line treatment of CML patients poses a 
minimal impact on the Colombian health care system, within parameters similar 
to those used in 2012 for the inclusion of technologies in the benefit plan. Additional 
benefits in lower progression rates and potential increased survival may favor this 
technology to be reimbursed within the premium (UPC) in Colombia.
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objeCtives: The purpose of this model is to examine the budgetary impact of the 
decision to reimburse crizotinib for patients with ALK+ve advanced non-small-cell 
A76  VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 1 - A 2 9 5  
PCN50
ClINICAl outComes ANd Budget ImPACt of CoBAs® egfr mutAtIoN test 
versus sANger sequeNCINg IN the treAtmeNt of loCAlly AdvANCed or 
metAstAtIC NsClC: A uNIted stAtes PAyer PersPeCtIve
Poulios N.1, Hertz D.2, Gavaghan M.2
1Roche Molecular Diagnostics, Pleasanton, CA, USA, 2GfK Market Access, Wayland, MA, USA
objeCtives: Personalized medicine has become standard of care in directing 
treatment with tyrosine kinase inhibitors in locally advanced or metastatic NSCLC 
patients, but various testing methods for identifying EGFR mutations exist. We 
compared the clinical outcomes and budget impact of using the FDA-approved 
cobas® EGFR Mutation Test versus Sanger sequencing for identifying EGFR muta-
tions in locally advanced or metastatic NSCLC patients from a US payer per-
spective. Methods: A decision-tree model was developed to compare testing 
methodologies and resulting treatment pathways in a hypothetical NSCLC US 
population health plan with 5 million covered lives and a baseline EGFR muta-
tion prevalence of 16.6%. Model inputs included parameters describing mutation 
testing accuracy treatment response (EGFR inhibitor, standard chemo therapy or 
best supportive care). Inputs were based on published literature and Medicare 
fee schedule reimbursement. Outcomes of the model included patients with test 
failures (based on detection limits of testing), average patient survival time and 
budget impact. Results: Patients whose samples were tested with the cobas® 
EGFR Mutation Test were less likely to experience test failures due to unusable tis-
sue samples compared to Sanger sequencing (6 test failures versus 57, respectively). 
Patients using the cobas® EGFR mutations testing received more appropriate care 
compared to Sanger sequencing (90% vs 82%, respectively), resulting in an average 
total survival increase of 0.6 months. Costs associated with diagnostic testing were 
$24,562 less than testing with Sanger sequencing, resulting in similar overall costs 
per member per month ($0.56). ConClusions: Performing EGFR mutation testing 
with the cobas® EGFR Mutation Test has advantages from both patient outcomes 
and payer budget impact perspectives. By correctly identifying more patients for 
proper treatment with less test failures, the cobas® EGFR Mutation Test is a cost-
effective strategy for identification of EGFR mutations in locally advanced or meta-
static NSCLC patients from a US payer perspective.
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objeCtives: Approximately 7,000 Canadians have multiple myeloma (MM). Without 
effective treatment, patients can suffer from a constellation of disease-related 
symptoms that significantly reduce quality of life and survival. Management of stem 
cell transplant (SCT) ineligible MM patients is complex and varied. Maintenance 
therapies (MTs) after various induction regimens have been shown to improve 
response rate and progression-free survival. We sought to compare Canadian costs 
between two common approaches to MT, either bortezomib or lenalidomide, in 
MM patients ineligible for SCT. Methods: The total annual drug cost of the two 
MT options were calculated and compared. Costs were based on 1.3mg/m2 of bort-
ezomib on days 1, 4, 8, 11 every three months, plus 50 mg of prednisone every 
other day, or 10 mg of lenalidomide on days 1 through 21 of each 28-day cycle. 
Administration costs including oncology nursing time and pharmacist workload, 
and pharmacy costs including a 10% markup and dispensing fees were added to the 
acquisition cost of bortezomib and lenalidomide, respectively. Unit and labour costs 
were obtained from public Canadian sources. Additional analyses were conducted 
to consider the impact of several variables including the management of adverse 
events, treatment duration and alternate costing assumptions. Results: The total 
annual costs of treatment per patient were $20,106, and $108,741 for bortezomib 
and lenalidomide, respectively. The incremental differences were robust to changes 
in inputs and assumptions (to be presented in poster). ConClusions: The results 
of this analysis suggest that substantial savings were associated with bortezomib 
MT when compared with lenalidomide MT. As drug costs represent an increasing 
proportion of public spending in Canada, it is important to consider both efficacy 
and cost of treatment. Further studies are required to determine the complete cost-
benefit of available MTs.
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objeCtives: In the UK, anastomotic leak rate after colorectal surgeries has been 
reported up to 19%. Yet, clinical and economic consequences of anastomotic leak 
have not been clearly articulated. Our study aims to estimate the clinical/economic 
burden of anastomotic leak following colorectal surgeries in the UK. Methods: The 
Hospital Episode Statistics database was used to identify English National Health 
Service Trust adult patients undergoing colorectal surgeries between January 2007 
and December 2011. Anastomotic leak was identified by re-intervention/diagnosis 
codes within a 30-day window following colorectal surgery, including re-opera-
tion, re-anastomosis, stent, colostomy, image guided drainage, washout procedure, 
abscess/drainage and diagnosis of generalized (acute) peritonitis. Hospital costs 
were calculated using Healthcare Resource Group and Department of Health refer-
ence index costs. Differences in outcomes between groups were compared using a 
propensity score matching approach, adjusting for age, gender, admission method, 
surgery type, comorbidity and medical stabilization. Results: A total of 131,689 
patients received colorectal surgeries (mean age: 65.2±15.4, male: 50.4%). The rate 
objeCtives: Based on evidence from the National Lung Cancer Screening Trial 
(NLST), the U.S. Preventive Services Task Force(USPSTF) recently recommended 
annual low-dose computed tomography(LDCT) screening for patients that are age 
55-80, have a 30 pack-year smoking history, and currently smoke or quit within the 
past 15 years. Under the terms of the Affordable Care Act, participating plans must 
cover this screening procedure. We project the 5-year clinical, resource, and budget 
impact of implementing this policy. Methods: We developed a forecasting model 
to estimate the 5-year incremental outcomes of implementing LDCT screening in 
accordance with USPSTF recommendations versus no screening. We considered 
commercial (age < 65) and Medicare (age 65+) populations with 165.1 million and 
51.7 million enrollees, respectively (in accordance with national insurance esti-
mates). Age-specific lung cancer detection rates and stage at diagnosis was derived 
from the NLST. Included costs were LDCT screening and follow-up, confirmatory 
bronchoscopy/biopsy, and stage-specific treatment (initial,continuing,terminal 
care). We estimated lung cancers detected, LDCT scans, and the total and per-
member per-month(PMPM) budget impact of covering LDCT screening, assuming 
100% adherence to USPSTF recommendations in the base case. Monetary results 
are reported in 2013 USD and discounted at 3% per year. Results: In commercial 
and Medicare plans, LDCT screening is expected to result in 84,000 and 141,000 
more lung cancers detected (predominantly Stage I),22.4 million and 37.5 million 
more LDCT scans,and increased overall expenditure of $16.4 billion(PMPM= $1.65) 
and $27.4 billion(PMPM= $8.84), respectively. The most influential parameters were 
the proportion of “high risk” patients electing to undergo screening, the rate of 
screening adoption in the community, and the initial treatment cost of early-stage 
lung cancer. ConClusions: Our analysis suggests that coverage of LDCT lung 
cancer screening is expected to increase lung cancer diagnoses,result in a greater 
proportion of early-stage disease diagnoses, and substantially increase health plan 
expenditure, particularly in Medicare.
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objeCtives: This study analyzes the cost of adverse events associated with 
metastatic renal cell carcinoma (mRCC) treatments of pazopanib and suni-
tinib. Methods: A cost analysis was performed based on the published data of 
the COMPARZ study. All adverse events (AEs) were identified based on the AEs 
reported in this study, Cost information related to the the treatment of the most 
frequent adverse events (> 15%) in the study population (n= 1,100 individuals) 
were obtained. These events included in the analysis were hepatotoxicity, anemia, 
nausea, fatigue and diarrhea. The perspective adopted in this analysis was of the 
Unified Health System (SUS) and Brazilian Supplementary Healthcare (SS). For reck-
oning purposes, the Medication Market Regulation Chamber (CMED/ ANVISA) listed 
prices were used. Results: From the perspective of the SUS, the following results 
are reported: nausea (sunitinib = BRL157.30 vs pazopanib = BRL176.49); anemia 
(sunitinib = BRL33.40 vs pazopanib = BRL14.32); fatigue (sunitinib = BRL18.00 vs 
pazopanib = BRL9.36); diarrhea (sunitinib = BRL73.09 vs pazopanib = BRL125.87) and 
hepatotoxicity (sunitinib = BRL416.18 vs pazopanib = BRL407.13). When consider-
ing costs incurred from private pay perspective such as SS, we observed the values 
were: nausea (sunitinib = BRL697.00 vs pazopanib = BRL782.00); anemia (sunitinib 
= BRL188.52 vs pazopanib = BRL80.79); fatigue (sunitinib = BRL163.11 vs pazopanib 
= BRL84.81) diarrhea (sunitinib = BRL248.66 vs pazopanib = BRL428.24) and hepa-
totoxicity (sunitinib = BRL2,080.90 vs pazopanib = BRL2,035.67). Thus, as from total 
estimated AE events cost, the SUS disbursed approximately BRL697.97 when the first 
line therapeutic option was sunitinib and BRL733.16 with pazopanib. In SS, it was 
paid around BRL3,378.18 and BRL3,411.51, respectively. ConClusions: A therapy 
that has less financial impact on the treatment of adverse events is the choice of 
sunitinib for both public (5% decrease) and private (1%) targets.
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objeCtives: A substantial proportion of prostate cancer care (PCa) is expected 
to be completed in the outpatient hospital setting, particularly as more hospitals 
systems acquire oncology practices. However, there is very limited information on 
practice-specific costs of care for patients receiving chemotherapeutic treatments 
within this unique setting. This study evaluated the cost of care for chemotherapy 
treatment in the outpatient hospital setting for PCa patients with bone metasta-
ses. Methods: Patients in the Premier Hospital Database between January 2006 
and December 2010 treated in an outpatient setting for PCa (ICD-9-CM Codes 185 
and 233.4) were selected. Patients were required to be ≥ 40 years of age and have no 
additional cancers and evidence of bone metastases (ICD-9-CM code 198.5 or the 
use of zoledronic acid or pamidronate disodium). Costs of care per visit across cost 
centers were evaluated and described. Results: There were 5,223 outpatient visits 
for men treated for PCa with bone metastases. The mean age of the sample was 71 
years, with 64% being Caucasian. The average visit cost was $4,614. Pharmacy costs 
($4,119) represent 89.2% of total visit costs, followed by professional ($190) and labo-
ratory expenses ($77). Chemotherapy costs represented 47% of total pharmacy costs, 
with the most commonly specified chemotherapies being docetaxel, mitoxantrone, 
and carboplatin. ConClusions: Men treated for PCa with bone metastases treated 
in an outpatient setting averaged $4,614 per visit, with pharmaceutical costs rep-
resenting almost 90% of care.
